Last reviewed · How we verify
Ademetionine IV+tablet
Ademetionine is a methyl donor that replenishes cellular methylation capacity and supports hepatic function and neurotransmitter synthesis.
Ademetionine is a methyl donor that replenishes cellular methylation capacity and supports hepatic function and neurotransmitter synthesis. Used for Cholestasis and liver disease, Hepatic cirrhosis, Drug-induced liver injury.
At a glance
| Generic name | Ademetionine IV+tablet |
|---|---|
| Sponsor | Abbott |
| Drug class | Methyl donor / Hepatoprotective agent |
| Target | S-adenosylmethionine synthetase substrate; indirect effects on methyltransferases and glutathione synthesis |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Ademetionine (S-adenosyl methionine, SAMe) is an endogenous compound that serves as the primary methyl donor in the body, facilitating methylation reactions essential for cell membrane integrity, neurotransmitter production, and antioxidant defense. It supports hepatocyte regeneration and reduces hepatic inflammation and fibrosis. The drug is thought to work through multiple pathways including enhancement of glutathione synthesis and modulation of cytokine production.
Approved indications
- Cholestasis and liver disease
- Hepatic cirrhosis
- Drug-induced liver injury
Common side effects
- Gastrointestinal disturbance
- Nausea
- Headache
- Diarrhea
Key clinical trials
- SAMe in Prevention of Oxaliplatin-associated Liver Injury (PHASE2)
- Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ademetionine IV+tablet CI brief — competitive landscape report
- Ademetionine IV+tablet updates RSS · CI watch RSS
- Abbott portfolio CI